ORTX - Orchard Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
1B
Enterprise Value 3
662.24M
Trailing P/E
N/A
Forward P/E 1
-5.50
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
385.03
Price/Book (mrq)
2.95
Enterprise Value/Revenue 3
254.02
Enterprise Value/EBITDA 6
-2.33

Trading Information

Stock Price History

Beta (3Y Monthly) N/A
52-Week Change 3-33.00%
S&P500 52-Week Change 315.09%
52 Week High 321.64
52 Week Low 38.65
50-Day Moving Average 311.89
200-Day Moving Average 314.36

Share Statistics

Avg Vol (3 month) 3202.64k
Avg Vol (10 day) 3218.96k
Shares Outstanding 596.52M
Float 69.29M
% Held by Insiders 10.00%
% Held by Institutions 158.40%
Shares Short (Oct 31, 2019) 42.08M
Short Ratio (Oct 31, 2019) 416.74
Short % of Float (Oct 31, 2019) 4N/A
Short % of Shares Outstanding (Oct 31, 2019) 42.15%
Shares Short (prior month Sep 30, 2019) 43.16M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-10,981.13%

Management Effectiveness

Return on Assets (ttm)-24.44%
Return on Equity (ttm)-43.95%

Income Statement

Revenue (ttm)2.61M
Revenue Per Share (ttm)0.03
Quarterly Revenue Growth (yoy)38.30%
Gross Profit (ttm)1.65M
EBITDA -284.74M
Net Income Avi to Common (ttm)-143.07M
Diluted EPS (ttm)-1.71
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)366.16M
Total Cash Per Share (mrq)3.79
Total Debt (mrq)24.61M
Total Debt/Equity (mrq)7.24
Current Ratio (mrq)8.88
Book Value Per Share (mrq)3.52

Cash Flow Statement

Operating Cash Flow (ttm)-150.76M
Levered Free Cash Flow (ttm)N/A